Taken together, this strategy unmasked two mutated transcription factor binding sites in AML cell line EOL-1 which modulated aberrant HMX2/3 expression via altered effects of ETS1 and ELK1, and of NFkB and SP1. This evidence concerns the gene SP1 and acute myeloid leukemia.